𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Occurrence of cytomegalovirus hepatitis in liver transplant patients

✍ Scribed by Oscar Bronsther; Leonard Makowka; Ronald Jaffe; A. Jake Demetris; Mary Kay Breinig; Monto Ho; Carlos O. Esquivel; Robert D. Gordon; Shunzaburo Iwatsuki; Andreas Tzakis; James W. Marsh Jr.; Vincenzo Mazzaferro; David Van Thiel; Dr. Thomas E. Starzl


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
783 KB
Volume
24
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


The differential diagnosis of liver dysfunction after orthotopic liver transplantation can be difficult. Cytomegalovirus (CMV) hepatitis is one possibility. This report reviews our experience with 17 cases of pathologically proven CMV hepatitis following liver transplantation and demonstrates the need for percutaneous liver biopsies to establish the diagnosis. There were seven pediatric patients (ages 2-1 1 years, five males, two females) and ten adult patients (ages 17-53 years, eight males, two females). The most common symptoms were prolonged fever (15 patients, with a mean duration of 22 2 5.5 days), elevation in total bilirubin (14 patients), and elevation in liver enzymes (1 5 patients); all symptoms were also found in rejection. Leukopenia and thrombocytopenia, reported to frequently occur with CMV infection, were found in only three and five patients, respectively.

Twelve patients with the above symptoms underwent percutaneous biopsy on one or more occasions to differentiate CMV hepatitis from rejection. The diagnosis was made at retransplantation in five patients. CMV hepatitis followed treatment for acute rejection in 14 patients and occurred without additional immunosuppression in three patients. All patients were maintained on cyclosporine and prednisone. Acute rejection episodes were treated with a 5-day tapering dose of steroids (1 7 courses in 12 patients), OKT3 monoclonal antibody [Ortho (4 patients)] antithymocyte globulin [llpjohn (2 patients)], and azathioprine (1 patient).

CMV was isolated from urine (nine patients), blood (nine patients), throat (seven patients), lungs (two patients), and other organs (two patients). CMV was cultured


📜 SIMILAR VOLUMES


Cytomegalovirus prophylaxis with valganc
✍ Hugo Wéclawiak; Nassim Kamar; Catherine Mengelle; Joëlle Guitard; Laure Esposito 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract The aims of this prospective, open‐label, single‐center pilot study were to assess the efficacy and safety of human cytomegalovirus (HCMV) prophylaxis using valganciclovir in HCMV‐ seropositive kidney‐transplant patients to prevent HCMV infection and disease. Fifty‐one HCMV seropositive

Hepatitis B in liver transplant recipien
✍ Robert G. Gish; Timothy McCashland 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

1. The use of low-dose immunosuppressive therapy along with pre- and posttransplantation nucleos(t)ide therapy and posttransplantation hepatitis B immunoglobulin (HBIG) has yielded marked improvements in survival. 2. Lamivudine (Epivir-HBV), adefovir (Hepsera), entecavir (Baraclude), tenofovir (Vire

Valganciclovir for cytomegalovirus proph
✍ Jeong M. Park; Kathleen D. Lake; Robert J. Fontana 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur